36 /100
MEDIUM RISK
Score updated Jul 13, 2026

XTLB — XTL Biopharmaceuticals Ltd. Dilution Risk Tracker

Track XTLB dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track XTLB — Get alerts when the score changes →

As of July 13, 2026, XTL Biopharmaceuticals Ltd. (XTLB) has a DilutionWatch DilutionScore of 36/100, rated MEDIUM dilution risk. XTL Biopharmaceuticals Ltd. has a market capitalization of $5.77M, 946.24M shares outstanding, 5 institutional holders tracked.

Source: DilutionWatch (dilutionwatch.com) — data updated daily from SEC EDGAR filings. Not financial advice.

📊 Score Breakdown

📋 Offering Ability
46
💰 Cash Runway
40
📊 Float Risk
2
⚠️ Warrant Exposure
40
🔄Convertible Debt

🌦️ Dilution Forecast

☀️
Clear
No significant dilution signals
0%
No significant dilution signals detected for XTLB.
🔔 Track XTLB — Get forecast alerts →

💹 Market Data

Market Cap$5.77M
Shares Outstanding946.24M
FloatN/A
Cash$259.0K
Debt$86.0K
Short InterestN/A

🏛 Institutional Holdings

5 institutional holders · 88.0K shares
#1 Noked Israel Ltd. 49.7K shares
#2 Citadel Advisors Llc 19.0K shares
#3 Smartharvest Portfolios, LLC 13.4K shares
+ 2 more holders Sign up free to view →

📉 Short Interest

Short Interest9.4K
Days to Cover1.0
% of FloatN/A
FINRA data as of Jun 30, 2026

📁 Recent SEC Activity

6-K 8K EVENT May 07, 2026
6-K 8K EVENT Apr 29, 2026
13F-HR BENEFICIAL OWNERSHIP Mar 31, 2026
13F-HR BENEFICIAL OWNERSHIP Mar 31, 2026
3 FORM3 Mar 23, 2026
Full SEC filing analysis available with free account

📰 Recent News

📋 What This Means for XTLB Shareholders

XTL Biopharmaceuticals Ltd. (XTLB) has a DilutionScore of 36/100, rated Medium dilution risk. This tier indicates some dilution exposure — often an older shelf registration with remaining capacity, warrants not yet exercised, or a cash position that will require monitoring over the next several quarters. Score as of July 13, 2026.

DilutionWatch's EDGAR monitoring for XTLB shows no major active dilution programs at this time. The primary risk categories — shelf registration capacity, ATM programs, warrant overhang, and cash runway — are each within normal ranges for a company of this profile. This can change quickly if a new S-3 or Form S-1 is filed.

DilutionWatch tracks over 25 SEC filing types for XTLB in real-time, scanning EDGAR every 60 seconds. The DilutionWatch screener shows real-time score changes for XTLB alongside comparable medium-risk stocks. Not financial advice — this analysis is for informational purposes only.

Track XTLB Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking XTLB — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

🔗 Related Stocks — MEDIUM Risk

Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:

Browse all 7,800+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
🔬 More Research for XTLB
📊 XTLB FDA Catalyst Timeline & Biotech Grade — BiotechSigns 📡 XTLB Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.